Application of galangin or salt thereof to preparation of medicines or health-care products capable of preventing and treating lung fibrosis

A technology of pulmonary fibrosis and galangin, applied in the field of medicine, can solve problems such as increased risk of respiratory failure, decreased immunity, liver and kidney damage, etc., and achieves significant clinical and social significance, good curative effect, and low toxicity.

Inactive Publication Date: 2019-08-30
SICHUAN UNIV
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Traditional treatment is mainly to suppress inflammation, but long-term use of glucocorticoids, immunosuppressants, cyclophosphamide and other drugs can cause liver and kidney damage, resulting in decreased immunity, and may induce new lesions or other diseases, increasing respiratory failure risk, and even cause severe secondary infection leading to death

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of galangin or salt thereof to preparation of medicines or health-care products capable of preventing and treating lung fibrosis
  • Application of galangin or salt thereof to preparation of medicines or health-care products capable of preventing and treating lung fibrosis
  • Application of galangin or salt thereof to preparation of medicines or health-care products capable of preventing and treating lung fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Example 1 In vitro cell experiment of galangin preventing and treating pulmonary fibrosis

[0030] The excessive proliferation of mouse embryonic fibroblasts (NIH3T3) and pancreatic cancer human alveolar basal epithelial cells (A549) can cause collagen deposition, therefore, inhibiting their proliferation can inhibit the expression and deposition of collagen.

[0031] In the process of pulmonary fibrosis, TGF-β is the main fibrosis factor, which can promote epithelial-mesenchymal transition (EMT) in vitro, inhibit the apoptosis of fibroblasts, and promote the production of reactive oxygen species; Studies have also shown that the massive release of TGF-β will accelerate the process of pulmonary fibrosis. After A549 is stimulated by TGF-β1, it will accelerate the process of epithelial-mesenchymal transition (EMT), and then accelerate the formation of pulmonary fibrosis. Therefore, inhibiting the transformation of EMT can reduce the formation of pulmonary fibrosis.

[00...

Embodiment 2

[0045] Example 2 In vivo animal experiment of galangin preventing and treating bleomycin-induced pulmonary fibrosis

[0046] Bleomycin (BLM) is a drug against squamous cell carcinoma, but it can cause pulmonary fibrosis. After bronchial infusion of bleomycin, type Ⅰ alveolar epithelial cells secrete pro-inflammatory factors after inflammatory injury, the proliferation and differentiation of type Ⅱ epithelial cells can be observed on the second day, myofibroblasts are recruited, synthesize collagen and Cause extracellular matrix accumulation, resulting in tissue and interstitial fibrosis. This is consistent with the induction of diffuse pulmonary fibrosis or fibrotic alveolitis in humans, suggesting that bleomycin-induced injury may provide a suitable model for this disease of unknown etiology and pathogenic mechanism. Based on this, this experiment established a bleomycin-induced pulmonary fibrosis model (CNV) in C57BL / 6 mice to evaluate the effect of galangin on pulmonary fi...

Embodiment 3

[0063] The in vitro safety evaluation of embodiment 3 galangin

[0064] 1. Cell Culture

[0065] Human normal hepatocytes (LO 2 ) was cultured with 10% FBS DMEM high-glucose medium, and 100 U / mL of penicillin and streptomycin were needed to be added during the cultivation and experiment process, and the environment conditions were 37°C, 5% CO 2 in the incubator.

[0066] 2. MTT method detects the effect of galangin on normal human liver cells (LO 2 ) Proliferation

[0067] Select cells in good logarithmic growth state, inoculate a 96-well plate according to the cell growth rate, about 1500-2000 cells per well, 100 μL per well, at 37 ° C, 5% CO 2 Incubator cultivation. On the second day after inoculation, add 100 μL of galangin dilution prepared with fresh medium to each well to make the final concentration 0 μmol / L, 6.25 μmol / L, 12.5 μmol / L, 25 μmol / L, 50 μmol / L, 100 μmol / L L, set 5 duplicate wells at the same concentration, at 37°C, 5% CO 2 After culturing in the incub...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an application of galangin or salt thereof to preparation of medicines or health-care products capable of preventing and treating lung fibrosis, and belongs to the field of medicines. In order to solve the problems that existing medicines capable of treating lung fibrosis are bad in treatment effects and the compliance of a patient is poor, the invention provides the application of galangin or salt thereof to preparation of medicines or health-care products capable of preventing and treating lung fibrosis. In vivo and in vitro experiment proves that the galangin can exert precise treatment effects of the lung fibrosis, and besides, is small in toxicity to human normal liver cells and good in safety. Through the application of the galangin and the salt thereof disclosed by the invention, providing medicines or health-care products which are good in treatment effects, low in toxicity and low in price for patients suffering from lung fibrosis is facilitated, and the application has remarkable clinical and social significance.

Description

technical field [0001] The invention relates to the use of galangin or a salt thereof in the preparation of medicines or health products for preventing and treating pulmonary fibrosis, and belongs to the field of medicine. Background technique [0002] Pulmonary fibrosis (lung fibrosis) is a chronic, progressive lung injury or lung disease to the end of the results. Its pathological features are massive proliferation of fibroblasts, accumulation of extracellular matrix in lung tissue accompanied by inflammatory damage, destruction of alveolar structure, and abnormal repair of tissue damage resulting in scar formation, which hinders the exchange of gas between the lungs and the outside world, eventually leading to respiratory failure. failure and death. The clinical symptoms of pulmonary fibrosis mainly include dyspnea, hypoxemia, and dry cough. With the deterioration of human living environment, pollution and other factors, the incidence of pulmonary fibrosis increases wit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P11/00
CPCA61K31/352A61P11/00
Inventor 阴文娅叶庭洪王礼群刘红垚张倩钰李亚丽甘彩玲
Owner SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap